GATA1: A key biomarker for predicting the prognosis of patients with diffuse large B-cell lymphoma.

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2025-05-07 eCollection Date: 2025-01-01 DOI:10.1515/med-2025-1185

Yuxin Zhang, Yue Wang, Shifen Wang, Dawei Cui, Zheng Wei

{"title":"GATA1: A key biomarker for predicting the prognosis of patients with diffuse large B-cell lymphoma.","authors":"Yuxin Zhang, Yue Wang, Shifen Wang, Dawei Cui, Zheng Wei","doi":"10.1515/med-2025-1185","DOIUrl":null,"url":null,"abstract":"Objectives: Diffuse large B-cell lymphoma (DLBCL) is a common and highly aggressive type of lymphoma. Iron metabolism plays a critical role in human diseases, however, which remains unclear in DLBCL patients. The study is to explore the genetic characteristics and molecular mechanisms underlying ferroptosis in DLBCL patients.Methods: Based on the GEO, GeneCards database, weighted gene co-expression network analysis was performed on the DLBCL sample and iron metabolism-related datasets. Enrichment analysis (Gene Ontology/Kyoto Encyclopedia of Genes and Genomes and gene set enrichment analysis) was used to analyze the expression and possible mechanism of key genes in DLBCL patients. The key genes were identified by quantitative real-time PCR.Results: The results showed that GATA-binding factor 1 (GATA1), as a key gene of iron metabolism in DLBCL patients, was related to the myeloid cell differentiation and granulocyte differentiation pathways to affect CD4+ T cells, B cells, and monocytes. GATA1 was strongly positively or negatively correlated with sensitivity to multiple targeted drugs. The patients with high GATA1 expression had shorter overall survival and worse prognosis than the patients with low expression. Additionally, high expression of the GATA1 gene was confirmed in DLBCL patients.Conclusions: GATA1 as one of the important genes of ferroptosis suggested a significant biomarker for predicting the prognosis of DLBCL patients.","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251185"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086623/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2025-1185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Diffuse large B-cell lymphoma (DLBCL) is a common and highly aggressive type of lymphoma. Iron metabolism plays a critical role in human diseases, however, which remains unclear in DLBCL patients. The study is to explore the genetic characteristics and molecular mechanisms underlying ferroptosis in DLBCL patients.

Methods: Based on the GEO, GeneCards database, weighted gene co-expression network analysis was performed on the DLBCL sample and iron metabolism-related datasets. Enrichment analysis (Gene Ontology/Kyoto Encyclopedia of Genes and Genomes and gene set enrichment analysis) was used to analyze the expression and possible mechanism of key genes in DLBCL patients. The key genes were identified by quantitative real-time PCR.

Results: The results showed that GATA-binding factor 1 (GATA1), as a key gene of iron metabolism in DLBCL patients, was related to the myeloid cell differentiation and granulocyte differentiation pathways to affect CD4⁺ T cells, B cells, and monocytes. GATA1 was strongly positively or negatively correlated with sensitivity to multiple targeted drugs. The patients with high GATA1 expression had shorter overall survival and worse prognosis than the patients with low expression. Additionally, high expression of the GATA1 gene was confirmed in DLBCL patients.

Conclusions: GATA1 as one of the important genes of ferroptosis suggested a significant biomarker for predicting the prognosis of DLBCL patients.

Abstract Image

查看原文本刊更多论文

GATA1：预测弥漫性大b细胞淋巴瘤患者预后的关键生物标志物。

目的：弥漫性大b细胞淋巴瘤（DLBCL）是一种常见的高侵袭性淋巴瘤。然而，铁代谢在人类疾病中起着关键作用，在DLBCL患者中仍不清楚。本研究旨在探讨DLBCL患者铁下垂的遗传特征和分子机制。方法：基于GEO、GeneCards数据库，对DLBCL样本和铁代谢相关数据集进行加权基因共表达网络分析。富集分析（Gene Ontology/Kyoto Encyclopedia of Genes and Genomes）和基因集富集分析（Gene set Enrichment analysis），分析关键基因在DLBCL患者中的表达及其可能机制。采用实时荧光定量PCR技术鉴定关键基因。结果：结果显示，gata结合因子1 （GATA1）作为DLBCL患者铁代谢的关键基因，与髓细胞分化和粒细胞分化通路相关，影响CD4+ T细胞、B细胞和单核细胞。GATA1与多靶点药物敏感性呈正相关或负相关。GATA1高表达患者总生存期较低表达患者短，预后较差。此外，在DLBCL患者中证实了高表达的GATA1基因。结论：GATA1作为铁下垂的重要基因之一，可作为预测DLBCL患者预后的重要生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.